Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Most relevant news about PFIZER
07/21PFIZER : Lambeth, Hanes forfeit money Reps. Lambeth and Hanes forfeit illegal ca..
AQ
07/21PFIZER : Trump plan fails to lower prescription drug prices
AQ
07/20PFIZER : U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim..
BU
07/20PFIZER : Biosimilar of Amgen's Neupogen Approved for Sale in the U.S.
DJ
07/20Swiss, German drugmakers join U.S. price freeze
RE
07/20PFIZER : At first glance
AQ
07/20PFIZER : Initiates Pivotal Phase 3 program for Investigational Hemophilia B Gene..
AQ
07/20MERCK AND : to Cut Drug Prices Amid Pressure -- WSJ
DJ
07/19PFIZER : Leaders from Pfizer, Sanofi, Eli Lilly and Applied Informatics to Speak..
AQ
07/19MERCK AND : to Limit Drug-Price Increases, Cut Some Prices
DJ
07/19Pfizer's tanezumab meets in Phase III for OA pain
AQ
07/19PFIZER : Novartis joins Pfizer in deferring drug-price hikes
AQ
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
07/18Pfizer, Lilly See Positive Top-Line Results From Phase 3 Trial of Tanezumab
DJ
More most relevant news
All news about PFIZER
07/21PFIZER : U.S. FDA Approves Pfizer's Biosimilar NIVESTYM (filgrastim-aafi)
AQ
07/21MERCK : Vyriads colorectal cancer oncolytic virus Voyager-V1
AQ
07/21SPARK THERAPEUTICS : Pfizer initiates Phase III programme for Sparks haemophilia..
AQ
07/21PFIZER : and Eli Lilly report positive results from Phase III tanezumab
AQ
07/21PFIZER : Lambeth, Hanes forfeit money Reps. Lambeth and Hanes forfeit illegal ca..
AQ
07/21PFIZER : Trump plan fails to lower prescription drug prices
AQ
07/20PFIZER : U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim..
BU
07/20PFIZER : Biosimilar of Amgen's Neupogen Approved for Sale in the U.S.
DJ
07/20Swiss, German drugmakers join U.S. price freeze
RE
07/20PFIZER : An Application for the Trademark "RUXIENCE" Has Been Filed by Pfizer
AQ
More news
Sector news : Pharmaceuticals - NEC
07/20GLAXOSMITHKLINE : considers splitting up the group - FT
RE
07/20PFIZER : Biosimilar of Amgen's Neupogen Approved for Sale in the U.S.
DJ
07/20BAYER : to Stop Selling Essure in U.S.
DJ
07/20GLAXOSMITHKLINE : considers splitting up the group
RE
07/20GLAXOSMITHKLINE : Mulls Separation of Consumer Division -- FT
DJ
07/20BAYER : to Stop Selling Essure in U.S.
DJ
More sector news : Pharmaceuticals - NEC
Official Publications
01/30Annual results 
01/30Slide show results 
2017SEC Filing 8K 
2017Slide show Q3 results 
20173rd quarter results 
2017SEC Filing 10Q-3 
More official Publications
News from SeekingAlpha
07/21STOCKS TO WATCH : FANGs Out In Tech 
07/20QUARTERLY REVIEW OF DIVGRO : Q2 2018 
07/20FDA OK's Pfizer's Neupogen biosimilar 
07/20YOUR DAILY PHARMA SCOOP : Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Posit.. 
07/19My Dividend Growth Portfolio - Q2 2018 Summary 
07/19Jane's June Dividend Increases And Income - Retirement Accounts 
Latest Tweets
02:10a. on Novartis and Pfizer's decisions not to raise drug prices: "This is the p..
25
07/21Pfizer gets FDA approval for drug similar to Amgen's Neupogen: Pfizer Inc. (p..
1
07/21Week in review: How Trump's policies moved stocks $DDAIF $FCAU $F $GM $HMC $N..
1
07/21Pfizer clearly hopes to run with its “little blue pill” as long as it can.  
07/21$PFE: Pfizer confirms receipt of FDA approval for its biosimilar NIVESTYM
2
More tweets
Qtime:487
Financials ($)
Sales 2018 54 297 M
EBIT 2018 20 769 M
Net income 2018 12 887 M
Debt 2018 21 973 M
Yield 2018 3,66%
P/E ratio 2018 17,18
P/E ratio 2019 15,61
EV / Sales 2018 4,43x
EV / Sales 2019 4,22x
Capitalization 219 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 39,8 $
Spread / Average Target 6,6%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER3.06%218 540
JOHNSON & JOHNSON-9.93%337 790
NOVARTIS-1.75%206 705
ROCHE HOLDING LTD.-5.90%200 737
MERCK AND COMPANY11.11%168 171
AMGEN9.54%126 889